"Xanthine Oxidase" is a descriptor in the National Library of Medicine's controlled vocabulary thesaurus,
MeSH (Medical Subject Headings). Descriptors are arranged in a hierarchical structure,
which enables searching at various levels of specificity.
An iron-molybdenum flavoprotein containing FLAVIN-ADENINE DINUCLEOTIDE that oxidizes hypoxanthine, some other purines and pterins, and aldehydes. Deficiency of the enzyme, an autosomal recessive trait, causes xanthinuria.
| Descriptor ID |
D014969
|
| MeSH Number(s) |
D08.811.682.047.928
|
| Concept/Terms |
Xanthine Oxidase- Xanthine Oxidase
- Oxidase, Xanthine
- Hypoxanthine Oxidase
- Oxidase, Hypoxanthine
- Purine-Xanthine Oxidase
- Oxidase, Purine-Xanthine
- Purine Xanthine Oxidase
- Hypoxanthine Dehydrogenase
- Dehydrogenase, Hypoxanthine
- Hypoxanthine-Xanthine Oxidase
- Hypoxanthine Xanthine Oxidase
- Oxidase, Hypoxanthine-Xanthine
|
Below are MeSH descriptors whose meaning is more general than "Xanthine Oxidase".
Below are MeSH descriptors whose meaning is more specific than "Xanthine Oxidase".
This graph shows the total number of publications written about "Xanthine Oxidase" by people in this website by year, and whether "Xanthine Oxidase" was a major or minor topic of these publications.
To see the data from this visualization as text,
click here.
| Year | Major Topic | Minor Topic | Total |
|---|
| 1994 | 0 | 1 | 1 |
| 1995 | 1 | 0 | 1 |
| 2000 | 0 | 1 | 1 |
| 2004 | 1 | 1 | 2 |
| 2005 | 0 | 1 | 1 |
| 2008 | 0 | 1 | 1 |
| 2010 | 0 | 1 | 1 |
| 2011 | 0 | 1 | 1 |
| 2013 | 1 | 1 | 2 |
| 2015 | 0 | 1 | 1 |
| 2022 | 1 | 0 | 1 |
To return to the timeline,
click here.
Below are the most recent publications written about "Xanthine Oxidase" by people in Profiles.
-
Racial Differences in XO (Xanthine Oxidase) and Mitochondrial DNA Damage-Associated Molecular Patterns in Resistant Hypertension. Hypertension. 2022 04; 79(4):775-784.
-
A Real-World Study of Switching From Allopurinol to Febuxostat in a Health Plan Database. J Clin Rheumatol. 2015 Dec; 21(8):411-8.
-
Serum and aqueous xanthine oxidase levels, and mRNA expression in anterior lens epithelial cells in pseudoexfoliation. Graefes Arch Clin Exp Ophthalmol. 2015 Jul; 253(7):1161-7.
-
Effects of Xanthine Oxidase Inhibition in Hyperuricemic Heart Failure Patients: The Xanthine Oxidase Inhibition for Hyperuricemic Heart Failure Patients (EXACT-HF) Study. Circulation. 2015 May 19; 131(20):1763-71.
-
Use of allopurinol in children with acute lymphoblastic leukemia to reduce skewed thiopurine metabolism. Pediatr Blood Cancer. 2014 Jun; 61(6):1114-7.
-
3,4-Dihydroxy-5-nitrobenzaldehyde (DHNB) is a potent inhibitor of xanthine oxidase: a potential therapeutic agent for treatment of hyperuricemia and gout. Biochem Pharmacol. 2013 Nov 01; 86(9):1328-37.
-
Potential contribution of oxidative stress and inflammation to anxiety and hypertension. Brain Res. 2011 Aug 02; 1404:63-71.
-
Oxidative stress: a potential recipe for anxiety, hypertension and insulin resistance. Brain Res. 2010 Nov 04; 1359:178-85.
-
Superoxide-induced potentiation in the hippocampus requires activation of ryanodine receptor type 3 and ERK. J Neurophysiol. 2008 Mar; 99(3):1565-71.
-
TNF-alpha contributes to endothelial dysfunction in ischemia/reperfusion injury. Arterioscler Thromb Vasc Biol. 2006 Mar; 26(3):475-80.